No Data
Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5
Express News | Veru Inc : Jefferies Cuts Target Price to $1 From $1.2
Express News | Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
More Unpleasant Surprises Could Be In Store For Veru Inc.'s (NASDAQ:VERU) Shares After Tumbling 39%
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
Russell 3000: Veru, Life MD Among Consumer Staple Additions; Benson Hill, PetMed Express Among Deletions
No Data
